ClinicalTrials.gg
RecruitingNCT07454187Updated Jul 10, 2026

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

A Phase 1/2 interventional study of SG2918 in Relapsed/Refractory Multiple Myeloma, sponsored by Hangzhou Sumgen Biotech Co., Ltd.. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Hangzhou Sumgen Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
201st of 406
40 · median 40
Started
2026
with 53 others
Phase 1/2
65 of 448
43 open now
Primary completion
2027-09
later than 166 of 274 live
Registered
403rd of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 201st largest by planned enrollment of the 406 interventional ones that give a count, is one of 54 that started in 2026, is one of 65 in phase 1/2, reaches primary completion later than 166 of the 274 other live ones, and was the 403rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

232 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.

Read the detailed description

This is a multicenter, open-label, dose-escalation and dose-expansion Phase Ib/II clinical study of SG2918 conducted in Chinese patients with relapsed/refractory multiple myeloma.The primary objective of this study is to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.Secondary objectives include exploring the efficacy, pharmacokinetic profile, pharmacodynamics, and immunogenicity of SG2918.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and ≤ 80 years.
  2. (ECOG) performance status score of 0-2.
  3. ≥ 3 months.
  4. Documented diagnosis of multiple myeloma.
  5. at screening (per IMWG criteria).
  6. Relevant laboratory values obtained within 7 days prior to the first dose must meet protocol-specified thresholds.
  7. Resolution of adverse events related to prior antineoplastic therapy to Grade ≤ 1 or baseline ( v6.0).
  8. Female participants of and male participants whose partners are of childbearing potential must use at least one acceptable method of during study treatment and for at least 7 months after the last dose.
  9. Male participants must refrain from sperm donation from the signing of the Form (ICF) until at least 7 months after the last study dose.

Exclusion criteria

Exclusion Criteria:

  1. Patients with primary multiple myeloma.
  2. Presence of non-bone-related extramedullary soft tissue plasmacytoma at screening.
  3. known meningeal or Central Nervous System involvement of multiple myeloma, or high suspicion of unconfirmed meningeal or Central Nervous System involvement.
  4. History of peripheral neuropathy of Grade ≥ 2.
  5. Active infection requiring systemic therapy within 2 weeks prior to the first dose.
  6. Hypertension that was not effectively controlled by standardized antihypertensive treatment within 2 weeks prior to the first dose, as judged by the investigator
  7. History of hypertensive crisis or hypertensive encephalopathy.
  8. Poorly controlled diabetes mellitus.
  9. Severe cardiovascular or cerebrovascular disease within 6 months prior to the first dose.
  10. Active or infection.
  11. Known history of active tuberculosis or active syphilis.
  12. Known to any component of the product.
  13. history of Grade 3-4 allergic reaction or life threatening hypersensitivity to any biological product.
  14. Received any of the following therapies or surgeries.

    1. Prior treatment with LILRB4 targeted therapy; or severe adverse reaction to prior MMAE containing therapy.
    2. Immunotherapy, macromolecular targeted therapy, or other antineoplastic biologic therapy within 28 days prior to the first dose.
    3. Cytotoxic chemotherapy or small molecule therapy within 14 days prior to the first dose.
    4. Modernized traditional Chinese herbal medicine with approved antineoplastic indications within 7 days prior to the first dose.
  15. Requirement for systemic (equivalent to > 10 mg prednisone per day) or other agents within 14 days prior to the first dose or during the study.
  16. Administration of any live or within 28 days prior to the first dose.
  17. Administration of other vaccines (e.g., inactivated COVID-19 vaccine) within 14 days prior to the first dose.
  18. Immune related toxicity during prior antineoplastic immunotherapy that resulted in permanent treatment discontinuation.
  19. Current or previous idiopathic pulmonary fibrosis or idiopathic pneumonia;
  20. Current acute pulmonary disease, interstitial lung disease, or pneumonia.
  21. Any other diagnosed within 5 years prior to the first dose.
  22. Documented history of neurological or psychiatric disorder.
  23. Any other condition that, in the opinion of the investigator, may render the participant unsuitable for study participation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SG2918 monotherapy

    Drug: SG2918

Interventions

  • DrugSG2918

    The study adopts a "3+3" dosing escalation approach. Initially, three dose groups are set, namely 1.5mg/kg, 1.8mg/kg, and 2mg/kg. The SG2918 will be administrated by intravenous infusion every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events(AEs )

    Number and percentage of AEs which is calculated by worst CTCAE grade by CTCAE 6.0

    Time frame: From time Day1 of Cycle1 until 30 days after last dose of SG2918

Secondary outcomes

  1. Pharmacokinetics(PK): Cmax

    Maximum drug concentration after administration

    Time frame: Through study completion, an average of one year

  2. Pharmacokinetics (PK): T1/2

    Elimination half-life of the drug after administration

    Time frame: Elimination half-life of the drug after administration

  3. Pharmacokinetics (PK): AUC

    Area Under the Curve of the drug after administration

    Time frame: Through study completion, an average of one year

  4. Immunogenicity

    Levels of anti-drug antibodies(ADAs) and neutralizing antibodies (tested in ADA-positive samples)

    Time frame: Through study completion, an average of one year

  5. objective response rate(ORR)

    percentage of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response

    Time frame: Through study completion, an average of one year

  6. PFS

    Progression-Free Survival

    Time frame: Through study completion, an average of one year

  7. MRD

    assessed by next-generation sequencing in bone marrow samples from participants who achieved CR or sCR, to determine the depth of response at the molecular level.

    Time frame: Through study completion, an average of one year

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 17 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 6, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454187
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Apr 16, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Yue Song
Contact
songyue@sumgenbio.com
+86-18511021346

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion